Premium
Artificial‐capillary‐systemdevelopment of human alloreactive cytotoxic T‐lymphocytes that lyse brain tumour
Author(s) -
Kruse Carol A.,
Beck L. Tony
Publication year - 1997
Publication title -
biotechnology and applied biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.468
H-Index - 70
eISSN - 1470-8744
pISSN - 0885-4513
DOI - 10.1111/j.1470-8744.1997.tb00433.x
Subject(s) - ctl* , cytotoxic t cell , cd8 , cytolysis , lysis , t lymphocyte , immunology , chemistry , biology , microbiology and biotechnology , in vitro , immune system , biochemistry
The production of alloreactive cytotoxic T‐lymphocytes (CTL) for therapy of recurrent brain tumours was performed in the CELLMAX® artificial capillary system composed of cell‐culture modules containing cellulose acetate or cuprammonium rayon hollow fibres. Lymphocytes, obtained from the brain‐tumour patient to be used for sensitization, were stimulated with OKT3 (anti‐CD3) and interleukin‐2 (IL‐2) and inoculated into the extracapillary space of artificial capillary modules. For allogeneic CTL production, the expanded patient lymphocytes were harvested, irradiated and placed into a second artificial capillary system with allogeneic lymphocytes from a healthy donor. In a one‐way mixed lymphocyte reaction, CTL developed in the presence of low‐concentration IL‐2 (60 i.u. of IL‐2/ml). In 18Ő21 days the cell preparation usually displayed a predominantly CD3 +, CD8 + phenotype, which consorted with the dual‐labelled CD8/CD11a markers used to identify CTL. Chromium (Cr)‐release assays demonstrated lysis of patient tumour in relation to allogeneic glioma; the response observed in cold‐target‐inhibition assays confirmed lysis of the relevant tumour by the CTL.